A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

HER2-Positive Solid Tumors Clinical Trial

Official title:

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity Profiles of the Recombinant Anti-HER2 and Anti-CD3 Humanized Bispecific Antibody (M802) in HER2-Positive Advanced Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04501770
• Other study ID #: M802001
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: August 28, 2021
• Est. completion date: December 31, 2023

Study information

• Verified date: July 2021
• Source: Wuhan YZY Biopharma Co., Ltd.
• Contact: Xiong Wang
• Phone: 86-027-82668440
• Email: wangxiong[@]yzybio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of different doses of M802 in patients with HER2-positive advanced solid tumors, and to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) so as to provide basis for the recommended phase 2 dose (RP2D).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 32
• Est. completion date: December 31, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males or females, aged =18 years old.

2. Patients must have a diagnosis of histologically or cytologically confirmed metastatic advanced solid tumor with failure to standard treatment and who have no available therapy that may confer clinical benefit. Patients with HER2-positive metastatic breast cancer should have received standard anti-HER2 therapies.

3. HER2 expression status report should be provided during the screening period with fluorescence in-situ hybridization (FISH) or Chromogenic in situ hybridization (CISH) test positive, or immunohistochemistry IHC 3+, or immunohistochemistry IHC 2+ and confirmed by amplification of FISH or CISH.

4. Patients must have stopped anti-tumor treatment for at least 4 weeks prior to the first dose of M802. The anti-tumor treatment includes chemotherapy, immunotherapy, targeted therapy, endocrine therapy, and radiotherapy (except for local radiation therapy for alleviating pain, at least 14 days after end of treatment).

5. Patients must have measurable lesions at baseline according to the RECIST Version 1.1.

6. Patients must have an ECOG performance status (PS) Score of 0-1.

7. Patients must have an expected survival > 12 weeks.

8. Patients must have a baseline left ventricular ejection fraction (LVEF) = 50%.

9. Patients must have adequate haematological and organ functions as indicated by the following laboratory values:

Haematological: Absolute Neutrophil Count (ANC) = 1.5 ×10^9/L; Blood Platelet Count (BPC) = 80 ×10^9/L; Hemoglobin = 9.0 g/dL (No blood transfusions within 14 days).

Hepatic: Bilirubin = 1.5 × upper limit of normal (ULN); AST and ALT = 2.5 × ULN (AST, ALT = 5 × ULN is allowed when there is liver metastasis).

Renal: Serum creatinine = 1.5 × ULN.

10. Patients must understand and voluntarily agree to participate by signing written informed consent.

Exclusion Criteria:

1. Patients who had prior treatment with trastuzumab or similar monoclonal drugs within 4 weeks before first dosing of M802.

2. Patients with brain metastasis.

3. Patients who have uncontrollable active infections (Grade = 2 according to CTCAE Version 5.0).

4. Patients with severe respiratory disease who are not suitable for the study at the judgment of investigator.

5. Patients with severe immunosuppression (long-term use of immunosuppressant or glucocorticoid with daily dosage of dexamethasone =10 mg).

6. Patients who have other malignant tumors in the past 5 years, except the complete cured cervical carcinoma in situ or basal cell or squamous cell carcinoma.

7. Patients with a history of serious cardiovascular disease, including receiving coronary artery bypass grafts or coronary stenting, occurrence of myocardial infarction, congestive heart failure within 6 months, or a history of unstable angina, uncontrolled severe hypertension or arrhythmia requiring medication.

8. Patients with a history of autoimmune diseases (e.g. inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis).

9. Patients with severe hyperthyroidism or hypothyroidism.

10. Patients with metabolic diseases such as uncontrolled diabetes, severe gastrointestinal bleeding, severe diarrhea (Grade = 2 according to CTCAE Version 5.0), or severe gastrointestinal obstruction requiring intervention.

11. Patients with a history of immunodeficiency, including HIV positive.

12. Patients with Hepatitis b surface antigen test positive or hepatitis c antibody test positive.

13. Patients who have received inoculation of (attenuated) live virus vaccine within 4 weeks before first dosing of M802.

14. Pregnant, lactating women, or females or males who have fertility plan within 12 months.

15. Patients with a previous history of definite neurological or psychiatric disorders, including epilepsy or dementia.

16. Patients who participated in clinical studies of other drugs within 4 weeks prior to first dosing of M802 (using last dosing of other drug's clinical studies as end).

17. Patients with adverse reactions from previous treatment haven't recovered to grade 1 according to CTCAE Version 5.0 (except for residual effect on hair loss).

Related Conditions & MeSH terms

• HER2-Positive Solid Tumors
• Neoplasms

Intervention

Drug:
• Chort 1 of M802
Cohort 1, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 2 µg, and the maintenance dose during core treatment period and extended treatment period is 5 µg.
• Chort 2 of M802
Cohort 2, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 5 µg, and the maintenance dose during core treatment period and extended treatment period is 10 µg.
• Cohort 3 of M802
Cohort 3, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 10 µg, and the maintenance dose during core treatment period and extended treatment period is 20 µg.
• Cohort 4 of M802
Cohort 4, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 20 µg, and the maintenance dose during core treatment period and extended treatment period is 50 µg.
• Cohort 5 of M802
Cohort 5, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 50 µg, and the maintenance dose during core treatment period and extended treatment period is 100 µg.
• Cohort 6 of M802
Cohort 6, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 100 µg, and the maintenance dose during core treatment period and extended treatment period is 150 µg.
• Cohort 7 of M802
Cohort 7, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1 is 150 µg, and on D8, D15, D22 is 225 µg.
• Cohort 8 of M802
Cohort 8, subjects will be administered M802 via intravenous infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. The starting dose is 225 µg, and the maintenance dose during core treatment period and extended treatment period is 300 µg.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wuhan YZY Biopharma Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD	Number of DLTs (dose limiting toxicities) during the first 28 days after the first administrations of study drug in each cohort.	From the time of first dosing (Day 1) until the forth dosing (Day 28)
Primary	RP2D	Incidence and severity of AEs, and SAEs, including but not limited to laboratory values, PK and biomarkers. All AEs will be classified as Grades 1 through 5 as defined by NCI CTCAE v5.0.	From the start of administration to the end of the study or 28 days after the administration is stopped (up to 1 years and 28 days)
Secondary	Area under the curve (AUC) of M802	The endpoints for assessment of PK of M802 include serum concentrations of M802 at different timepoints after M802 administration.	From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).
Secondary	Maximum observed concentration (Cmax) of M802	The endpoints for assessment of PK of M802 include serum concentrations of M802 at different timepoints after M802 administration.	From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).
Secondary	Minimum observed concentration (Cmin) of M802	The endpoints for assessment of PK of M802 include serum concentrations of M802 at different timepoints after M802 administration.	From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).
Secondary	Expression levels of CEA	As tumor marker, expression levels of CEA will be tested in hospitals.	From the time of screening period until disease progression or toxicity intolerance (up to 1 years and 28 days).
Secondary	Expression levels of CA15-3	As tumor marker, expression levels of CA15-3 will be tested in hospitals.	From the time of screening period until disease progression or toxicity intolerance (up to 1 years and 28 days).
Secondary	Expression levels of CA125	As tumor marker, expression levels of CA125 will be tested in hospitals.	From the time of screening period until disease progression or toxicity intolerance (up to 1 years and 28 days).
Secondary	Expression levels of CA19-9	As tumor marker, expression levels of CA19-9 will be tested in hospitals.	From the time of screening period until disease progression or toxicity intolerance (up to 1 years and 28 days).
Secondary	Expression levels of CA72-4	As tumor marker, expression levels of CA72-4 will be tested in hospitals.	From the time of screening period until disease progression or toxicity intolerance (up to 1 years and 28 days).
Secondary	Cytokines	The levels of pharmacodynamic cytokines will be determined at the PD central laboratory.	From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).
Secondary	Number of subjects who develop detectable anti-drug antibodies (ADAs)	The immunogenicity of M802 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).	From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).
Secondary	The antibody titer of the neutralizing antibody	The immunogenicity of M802 will be collected by testing the antibody titer of the neutralizing antibody.	From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).
Secondary	ORR	Objective response rate (ORR) is defined as the proportion of patients with complete response (CR) and partial response (PR), based on RECIST Version 1.1.	From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).
Secondary	DCR	Disease Control Rate (DCR) is defined as the proportion of patients with complete response (CR) and partial response (PR), based on RECIST Version 1.1.	From the time of first dosing (Day 1) until disease progression or toxicity intolerance (up to 1 years).